IL-21 and Sjögren's syndrome

Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis

(2011) J. Bowes et al.   ANNALS OF THE RHEUMATIC DISEASES

Impact of interleukin-21 in the pathogenesis of primary Sjogren's syndrome: increased serum levels of interleukin-21 and its expression in the labial salivary glands

(2011) Kwi Kang et al.   ARTHRITIS RESEARCH & THERAPY

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

(2010) P. Quartier et al.   ANNALS OF THE RHEUMATIC DISEASES

Autoinflammatory Disease Reloaded: A Clinical Perspective

(2010) Daniel L. Kastner et al.   CELL

Anti-TNF Therapy, from Rationale to Standard of Care: What Lessons Has It Taught Us?

(2010) M. Feldmann et al.   JOURNAL OF IMMUNOLOGY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET

Neutralizing IL-21 and IL-15 Inhibits Pro-inflammatory Cytokine Production in Rheumatoid Arthritis

(2008) A. K. Andersson et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY